Maegim한국어

종근당홀딩스

001630KOSPISector: Pharma & Biotech
₩38,200▲ 1.19%Market cap ₩191.4BAs of Jul 21, 2026 close · updated once daily
A
Grade A70.1 ptsTop 11% of 2,523 stocks
Financial strength
50.5
Growth momentum
62.1
Price attractiveness
98.2

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

50.5
How much debt does it carry relative to equity?
Debt-to-equity ratio
78.4%
✗ Below median · Top 65.7% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
81.1%
✗ Below median · Top 82.7% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
6.1%
✓ Above median · Top 25.7% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
6.3%
✓ Above median · Top 23.8% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

62.1
How much did revenue grow in a year?
Revenue growth (YoY)
0.1%
✗ Below median · Top 66.9% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
1.8%
✗ Below median · Top 61.8% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
64.2%
✓ Above median · Top 17.2% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
277.3%
✓ Above median · Top 5.6% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

98.2
Is the price expensive relative to earnings?
P/E (price-to-earnings)
4.7x
✓ Above median · Top 1.4% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.30x
✓ Above median · Top 2.2% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15